PATENT APPLICATION

05213-0880 DIV Attorney Docket No. First Inventor Michael O'REILLY et al. Nucleic Acids Encoding Therapeutic Antiangiogenic Endostatin Title Composition

TRANSMITTAL

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Only lot 1	iew nonprovision	ai applications under 37 C	J.F.K. 1.03(0))	Express iviali i	aber no.		<u>v</u>			
APPLICATION ELEMENTS					Assistant Commissioner for Patents ADDRESS TO: Box Patent Application					
		erning utility patent applic			n, DC 20231					
2. 🛛 , , , , , , , , , , , , , , , , , ,	Submit an original a Applicant claim: See 37 CFR 1.2 Specification preferred arrange Descriptive title of Cross Reference Statement Rega	[Total Fement set forth below]	Pages 65]	8. Nucle (if ap a. ⊠ b. Sp i. [ii. [7. □ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. ☒ Computer Readable Form (CRF) b. Specification Sequence Listing on: □ CD-ROM or CD-R (2 copies); or ☒ paper Statements verifying identity of above copies 					
_	or a computer pr		ACCOMPANYING APPLICATIONS PARTS							
- - -	Background of the Invention Brief Summary of the Invention Brief Description of the Drawings (if filed) Detailed Description Claim(s) Abstract of the Disclosure			9. 🛭 10. 🗌	Assignme		er sheet & document(s)) \footnote{\square} hent \text{Power of}			
_	Abstract of the L	isclosure		11.	11. English Translation Document (if applicable)					
4. Drawing(s) (35 U.S.C.113) [Total Sheets 14] 5. Oath or Declaration [Total Pages 2]					12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations					
а. 🗌	Newly execute	ed (original or copy)	<u> </u>	13. 🔲	Preliminar	y Amendment				
b. 🛚	Copy from a p	rior application (37 CF	FR 1.63 (d))	14. 🛚	14. A Return Receipt Postcard (MPEP 503) (Should be specifically itemized)					
	(for a continue	ation/divisional with Bo	ox 18 completed)	15.	•		•			
i [OF INVENTOR(S)		10.	 Certified Copy of Priority Document(s) (if foreign priority is claimed) 					
		ent attached deleting inver rior application, see 37 CI		16. 🗌						
	1 63(d)(2) and		118	1	(b)(2)(B)(i). Applicant must attach form PTO/SB/35					
6. 🗍 Apı		Sheet. See 37 CFR 1.7	76	1	or its equiv					
				17. □	17. Other:					
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: □ Continuation □ Divisional □ Continuation-in-part (CIP) of prior application No. 09 / 315689 Prior application information: Examiner Sheela J. Huff Group / Art Unit: 1642 For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.										
			17. CORRESPO	NDENCE AL	DRESS					
☐ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here)										
	Houri Khalilian, Ph.D.									
Name 	Kilpatrick Sto	Kilpatrick Stockton LLP								
Address	1100 Peachtr	ee Street								
	Suite 2800									
City	Atlanta		State	GA		Zip Code	30309-4530			
Country	USA	7	Telephone	(202) 508-	5800	Fax	(202) 508-5858			
Name (Print/Type) Houri Khalilian		Registration	Registration No. (Attorney/Agent) 39,459		39,459					
Signature		HV		Date		January 11, 2002				

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision,

Complete if Known				
Application Number	To be Assigned			
Filing Date	Herewith			
First Named Inventor	Michael O'Reilly et al.			
Examiner Name	To be Assigned			
Group / Art Unit	To be Assigned			
	l			

TOTAL AMOUNT OF PAYMENT (\$) 410 05213-0880 DIV Attorney Docket No. METHOD OF PAYMENT (check all that apply) FEE CALCULATION (continued) 3. ADDITIONAL FEES Large Entity Small Entity Order ☐ Deposit Account Fee Fee Description Code (\$) Code (\$) Paid 105 130 205 Deposit Surcharge - late filing fee or oath 65 Kilpatrick Stockton, LLP Account 127 50 227 25 Surcharge - late provisional filing fee Number or cover sheet 139 130 139 130 Non-English specification Deposit 147 2.520 147 2.520 For filing a request for reexamination 11-0855 Account 112 920* 112 Requesting publication of SIR prior to Name Examiner action The Commissioner is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☑ Credit any overpayments 113 1.8401 113 1,840* Requesting publication of SIR after Examiner action Charge any additional fee(s) during the pendency of this application 115 110 215 55 Extension for reply within first month Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account 116 400 216 200 Extension for reply within second **FEE CALCULATION** 117 920 217 460 Extension for reply within third month BASIC FILING FEE 118 218 720 1,440 Extension for reply within fourth **Entity Small** Entity month Large 128 Fee Description 1.960 228 980 Extension for reply within fifth month Code (\$) Code (\$) Fee Paid 119 320 219 160 Notice of Appeal 101 740 201 370 Utility filing fee 370 120 320 220 160 Filing a brief in support of an appeal 106 330 206 165 Design filing fee 121 280 221 140 Request for oral hearing 107 510 207 255 Plant filing fee Petition to institute a public use 138 1,510 138 1,510 108 740 208 370 Reissue filing fee proceeding 114 160 80 Provisional filling fee 140 110 240 55 214 Petition to revive - unavoidable 141 241 1,280 640 Petition to revive - unintentional SUBTOTAL (1) (\$) 370 142 1,280 242 640 Utility issue fee (or reissue) 143 460 2. EXTRA CLAIM FEES 243 230 Design issue fee 144 620 244 310 Plant issue fee Extra Fee from Fee Claims below Paid 122 130 122 130 Petitions to the Commissioner Total Claims 20 -20 0 Х 0 18 123 50 123 50 Processing fee under 37 CFR 1.17 (q) Independent Submission of Information Disclosure 2 0 -3 * X 84 0 126 180 126 180 Stmt Multiple Recording each patent assignment 0 280 0 per property (times number of Dependent 581 40 581 40 40 nn properties) Entity Smail Entity Large 146 740 246 370 Filing a submission after final rejection (37 CFR § 1.129(a)) Fee Description Code (\$) Code (\$) 149 740 249 370 For each additional invention to be 18 203 Claims in excess of 20 examined (37 CFR § 1.129(b)) 102 84 202 42 Independent claims in excess of 3 179 740 279 Request for Continued Examination (RCE) 370 104 280 204 140 Multiple dependent claim, if not paid ** Reissue independent claims over 169 900 169 Request for expedited examination 109 209 42 original patent of a design application ** Reissue claims in excess of 20 and 110 18 210 over original patent Other fee (specify) SUBTOTAL (2) (\$)0 *Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 40 **or number previously paid, if greater, For Reissues, see above

SUBMITTED BY Complete (if applicable)									
Name (Print/Type)	Houri Khalilian, Ph D.	Registration No. Attorney/Agent)	39,459	Telephone	(202) 508-5800				
Signature				Date	January 11, 2002				

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Michael O'REILLY et al.

Art Unit:

Huff, S.

Serial No.:

To be Assigned

Examiner:

1642

Filed:

Herewith

For:

THERAPEUTIC ANTIANGIOGENIC ENDOSTATIN COMPOSITIONS

TRANSMITTAL OF SEQUENCE LISTING UNDER 37 C.F.R. § 1.821

Assistant Commissioner for Patents Washington, DC 20231

Sir:

Applicants submitt herewith a paper copy containing the Sequence Listing.

Respectfully submitted

KILPATRICK STOCKTON LLP

607 14th Street, N.W., Suite 900 Washington, D.C. 20005

(202) 508-5800

(202) 508-5858 FAX

By:

Houri Khalilian,

Registration No. 39,549